Ernexa Therapeutics (ERNAW) Operating Leases (2018 - 2026)
Ernexa Therapeutics (ERNAW) reported Operating Leases of $226000.0 for Q1 2026, down 64.24% on a YoY basis from $632000.0 in Q1 2025, and down 53.88% quarter-over-quarter from $490000.0 in Q4 2025.
Ernexa Therapeutics (ERNAW) Operating Leases (2018 - 2026) Analysis & Trends
Ernexa Therapeutics has reported Operating Leases for 9 years, with the latest figure at $226000.0 in Q1 2026.
- For the quarter ending Q1 2026, Operating Leases fell 64.24% year-over-year to $226000.0; the trailing twelve-month figure through Mar 2026 stood at $226000.0 (down 64.24% YoY), and the FY2025 full-year result was $490000.0, down 28.36% from the prior year.
- Operating Leases for Q1 2026 stood at $226000.0, down from $490000.0 in the prior quarter.
- The five-year high for Operating Leases was $40.3 million in Q2 2024, with the low at $226000.0 in Q1 2026.
- Historically, Operating Leases has averaged $11.3 million across 5 years, with a median of $887000.0 in 2022.
- Annual changes were most pronounced in 2024 — Operating Leases soared 4247.8% — and 2025, when it slumped 99.07%.
- Ernexa Therapeutics' Operating Leases stood at $887000.0 in 2022, then surged by 3853.78% to $35.1 million in 2023, then slumped by 98.05% to $684000.0 in 2024, then declined by 28.36% to $490000.0 in 2025, then plunged by 53.88% to $226000.0 in 2026.
- The last three Operating Leases figures came in at $226000.0 (Q1 2026), $490000.0 (Q4 2025), and $346000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ernexa Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 226,000.00 |
| Dec 31, 2025 | 490,000.00 |
| Sep 30, 2025 | 346,000.00 |
| Jun 30, 2025 | 376,000.00 |
| Mar 31, 2025 | 632,000.00 |
| Dec 31, 2024 | 684,000.00 |
| Sep 30, 2024 | 534,000.00 |
| Jun 30, 2024 | 40.31 Mn |
| Mar 31, 2024 | 36.57 Mn |
| Dec 31, 2023 | 35.07 Mn |
| Sep 30, 2023 | 35.00 Mn |
| Jun 30, 2023 | 34.96 Mn |
| Mar 31, 2023 | 841,000.00 |
| Dec 31, 2022 | 887,000.00 |
| Sep 30, 2022 | 2.32 Mn |
| Jun 30, 2022 | 2.43 Mn |
| Mar 31, 2022 | 1.02 Mn |
| Dec 31, 2021 | 2.30 Mn |
| Sep 30, 2021 | 2.41 Mn |
| Jun 30, 2021 | 2.53 Mn |